Viimane versioon :
08/05/2024
Vähiravimite   Mercaptopurine  
Suukaudne lahus
Stabiilsust ravimpreparaadid Stabiilsust mõjutavad tegurid Stabiilsust mõjutavad faktorid Sobimatus Viited Pdf
   Keemiline struktuur  

Suukaudne lahus
Viited   Suukaudne lahus   Viited : Mercaptopurine  
Tüüp Avaldamine
2396 Ajaleht Aliabadi HM, Romanick M, Desai S, Lavasanifar A.
Effect of buffer and antioxidant on stability of a mercaptopurine suspension
Am J Health-Syst Pharm 2008 ; 65: 441-447.
3244 Plakat Sutra C, Guillemot C, Monnier S, Puiset F, Canonge JM.
Stabilité chimique et microbiologique d'une suspension de mercaptopurine à 5 mg/mL.
SFPO Congress Mandelieu, France 2011
3843 Ajaleht Peacock G.F, Sauvageot J, Hill A, Killian A.
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
Int J Pharm Compound 2016 ; 20, 1: 81-85
4177 Ajaleht Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526

  Mentions Légales